American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world treatment patterns and outcomes of patients with chronic lymphocytic leukemia (CLL) receiving first-line (1L) therapy in the United States (US)
    Meeting Abstract

    Mato, A. R.; Ravelo, A.; To, T. M; Schuldt, R.; Biondo, J. M. L.
    Blood (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Mcm2 deficiency leads to bone marrow failure and lymphoid malignancies dependent on age and genetic background
    Meeting Abstract

    Matsukawa, T.; Yin, M.; Baslan, T.; Chung, Y. J.; Cao, D.; Bertoli, R.; Zhu, J.; Walker, R. L.; Freeland, A.; Knudsen, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
    Meeting Abstract

    Mascarenhas, J.; Harrison, C. N.; Gerds, A. T.; Prchal, J. T.; Rampal, R.; Buckley, S. A.; Craig, A. R.; Smith, J. A.; Volpone, J.; Roman-Torres, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Treatment of myelofibrosis patients with the TGF-β 1/3 inhibitor AVID200 (MPN-RC 118) induces a profound effect on platelet production
    Meeting Abstract

    Mascarenhas, J.; Kosiorek, H. E.; Bhave, R.; Palmer, J. M.; Kuykendall, A. T.; Mesa, R. A.; Rampal, R.; Gerds, A. T.; Yacoub, A.; Pettit, K. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • POLARGO: Randomized phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Matasar, M. J.; Haioun, C.; Sancho, J. M.; Viardot, A.; Hirata, J.; Perretti, T.; Musick, L.; McMillan, A. K.
    Blood (2021)

    Fulltext@MSK | Save
  • Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Liedtke, M.; Sidana, S.; Matous, J. V.; Chhabra, S.; Oluwole, O. O.; Malik, S. A.; Kumar, S.; Nath, R.; Anwer, F.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease
    Meeting Abstract

    Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Updated results from CARTITUDE-1: Phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Usmani, S. Z.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Hari, P.; Avigan, D.; Deol, A.; Htut, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Defining new reference intervals for serum free light chains in individuals with reduced kidney function: Results of the population- based on Iceland screens treats or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Long, T. E.; Indridason, O. S.; Palsson, R.; Rögnvaldsson, S.; Love, T. J.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2021)

    Fulltext@MSK | Save